Truist lowered the firm’s price target on Humana to $530 from $590 and keeps a Hold rating on the shares as part of a broader research note on Healthcare Services names. The analyst cites the recent market moves and updates in multiples following commentary from both UnitedHealth (UNH) and Humana around an uptick in utilization, reducing targets in Managed Care and bumping Hospital targets while remaining “broadly bullish” on both groups.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HUM:
- Wells Fargo Sees Potential Purchase Window in Managed Care Stocks
- Humana price target lowered to $585 from $620 at Barclays
- Evolent selloff on MCOs’ utilization comments ‘way overdone,’ says RBC Capital
- Humana management to meet with Truist
- Humana backs FY23 adjusted EPS view of ‘at least’ $28.25, consensus $28.34